STOCK TITAN

Neogen shareholders elect directors, ratify BDO; pay vote falls short

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Neogen Corporation reported results from its 2025 Annual Meeting held on October 23, 2025. A total of 195,086,461 of 217,298,626 shares outstanding and entitled to vote were represented.

Shareholders elected four directors: Thierry L. Bernard (For 168,950,135; Withheld 16,330,540), Mikhael Nassif (For 171,847,536; Withheld 13,433,139), Avi Pelossof (For 171,839,634; Withheld 13,441,041), and Andrea F. Wainer (For 169,573,203; Withheld 15,707,472).

The non-binding advisory vote on executive compensation did not pass (For 167,126,873; Against 17,679,601; Abstain 412,667; Broker Non-Vote 9,805,786). Shareholders ratified BDO USA, P.C. as independent auditor for the fiscal year ending May 31, 2026 (For 181,630,320; Against 13,148,285; Abstain 307,856).

Positive

  • None.

Negative

  • None.

Insights

Directors elected; say-on-pay failed; auditor ratified.

Neogen’s meeting confirms board continuity with four nominees elected by sizable majorities. The advisory vote on executive pay did not receive approval, signaling shareholder dissatisfaction with the compensation program as disclosed in the proxy. Auditor continuity is affirmed with the ratification of BDO USA, P.C. for the fiscal year ending May 31, 2026.

Advisory votes are non-binding, but boards often review program design and engagement when support falls short. The vote tallies provide clear signals: pay received fewer “For” votes than the director slate, while the auditor received broad support.

Subsequent filings may provide the board’s response to the advisory outcome and any adjustments to compensation practices disclosed in future proxy materials.

false000071137700007113772025-10-232025-10-23

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2025

 

 

Neogen Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Michigan

0-17988

38-2367843

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

620 Lesher Place

 

Lansing, Michigan

 

48912

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (517) 372-9200

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.16 par value per share

 

NEOG

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 23, 2025, the Company held its 2025 Annual Meeting of Shareholders. At the meeting, 195,086,461 of the 217,298,626 shares outstanding and entitled to vote were present and voted. The matters listed below were submitted to a vote of the shareholders though the solicitation of proxies. The proposals are described in detail in the Company’s Proxy Statement dated as of, and filed with Securities and Exchange Commission on, September 12, 2025. The voting results are as follows:

 

Proposal 1 – Election of Directors

 

Nominee

For

Withheld

Thierry L. Bernard

 

 

168,950,135

 

 

 

16,330,540

Mikhael Nassif

 

 

171,847,536

 

 

 

13,433,139

Avi Pelossof

 

 

171,839,634

 

 

 

13,441,041

Andrea F. Wainer

 

 

169,573,203

 

 

 

15,707,472

 

 

 

Proposal 2 – To Approve, by Non-Binding Vote, the Compensation of the Company’s Named Executive Officers

The shareholders did not approve, by non-binding vote, the compensation of the Company’s named executive officers, as disclosed in the proxy materials.

For

Against

Abstain

Broker Non-Vote

167,126,873

 

 

 

17,679,601

 

 

 

412,667

 

 

 

9,805,786

 

Proposal 3 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm

The shareholders ratified the appointment of BDO USA, P.C. as the Company’s auditors for the fiscal year ending May 31, 2026.

For

Against

Abstain

Broker Non-Vote

181,630,320

 

 

 

13,148,285

 

 

 

307,856

-


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

NEOGEN CORPORATION

 

 

 

 

Date:

October 27, 2025

By:

/s/ Amy M. Rocklin

 

 

 

Name: Amy M. Rocklin
Title: Chief Legal & Compliance Officer, Corporate Secretary

 


Neogen Corp

NASDAQ:NEOG

NEOG Rankings

NEOG Latest News

NEOG Latest SEC Filings

NEOG Stock Data

1.55B
215.36M
0.85%
112.78%
8.46%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
LANSING